DNL343
DNLI-F-0003
Phase 3 small_molecule completed
Quick answer
DNL343 for Amyotrophic Lateral Sclerosis is a Phase 3 program (small_molecule) at Denali Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Amyotrophic Lateral Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed